[
  {
    "ts": null,
    "headline": "Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal",
    "summary": "Abbott Laboratories, NYSE:ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is also increasing focus on diabetes and cardiovascular products as part of a broader transformation. Abbott Laboratories, NYSE:ABT, is in the middle of a significant reset as it contends with persistent pressure in its Nutrition business. The stock closed at $109.3, with...",
    "url": "https://finnhub.io/api/news?id=2bcf61d19605f6e429f093f215793de4896d0be6df76ed0fb4da667e6aa5f4cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769879433,
      "headline": "Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal",
      "id": 138316673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories, NYSE:ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is also increasing focus on diabetes and cardiovascular products as part of a broader transformation. Abbott Laboratories, NYSE:ABT, is in the middle of a significant reset as it contends with persistent pressure in its Nutrition business. The stock closed at $109.3, with...",
      "url": "https://finnhub.io/api/news?id=2bcf61d19605f6e429f093f215793de4896d0be6df76ed0fb4da667e6aa5f4cc"
    }
  },
  {
    "ts": null,
    "headline": "The DGI Core Portfolio: 2025 Year-End Review",
    "summary": "The DGI Core Portfolio: 2025 Year-End Review",
    "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769847300,
      "headline": "The DGI Core Portfolio: 2025 Year-End Review",
      "id": 138314876,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For February 2026",
    "summary": "Dividend Aristocrats lagged the S&P 500 in 2025 but started 2026 strong.",
    "url": "https://finnhub.io/api/news?id=800289596e0fb58f29b2e1070377b29fa7b3a4d167bb115d6581677c59423fb0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769833874,
      "headline": "Best Dividend Aristocrats For February 2026",
      "id": 138313889,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249594654/image_2249594654.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats lagged the S&P 500 in 2025 but started 2026 strong.",
      "url": "https://finnhub.io/api/news?id=800289596e0fb58f29b2e1070377b29fa7b3a4d167bb115d6581677c59423fb0"
    }
  }
]